Eye Gene consortium begins first-phase clinical trial dosing of COVID-19 mRNA vaccine
Predicted impact: Medium
Phase 1 dosing start for a small biotech; meaningful milestone, size unknown.
Eye Gene아이진
185490 · KOSDAQ · ₩185490 · 아이진
₩1,705▼ ₩45 (2.57%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y −7.49%
- Market cap
- ₩74B
- Enterprise value
- ₩38B
- P/E
- —
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- −34.9%
- Net margin
- −391.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−39.2% from the high
₩1,182Today: ₩1,696 – ₩1,762₩2,805
Returns
- 1W−5.4%
- 1M−11.9%
- 3M+16.1%
- 6M+19.1%
- YTD−2.0%
- 1Y−7.5%
- Volume today
- 39,988
- 0.6× the 20-day average
- Traded today
- ₩69M
- Listed shares
- 43,229,784
- EPS (12 months)
- −₩406
- Earnings yield −23.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.3% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Eye Gene stock overview
Eye Gene (아이진, KRX: 185490) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech venture focused on research and development in medicine and pharmaceuticals, with a focus on next-generation gene and cell therapies and vaccines for intractable and genetic diseases. Its shares closed at ₩1,705 on Oct 30, 2026, down 2.57% on the day, giving it a market value of ₩74B.
Key facts
- Market cap
- ₩74B
- Sector
- Biotech & Pharma
- Latest price change
- −2.57%
- As of
- Oct 30, 2026
- Main business
- The company is a Korean biotech venture focused on research and development in medicine and pharmaceuticals, with a focus on next-generation gene and cell therapies and vaccines for intractable and genetic diseases.
Quick answers about Eye Gene
- What does Eye Gene do?
- The company is a Korean biotech venture focused on research and development in medicine and pharmaceuticals, with a focus on next-generation gene and cell therapies and vaccines for intractable and genetic diseases. Its main pipelines include an mRNA-based COVID-19 vaccine using a self-amplifying RNA platform developed with consortium partners, and an AAV gene therapy targeting wet age-related macular degeneration and diabetic retinopathy. It also develops a tetravalent meningococcal conjugate vaccine, a recombinant botulinum toxin with Korea BMI, and sells pharmaceuticals through its wholesale business.
- What is the market cap of Eye Gene?
- The market capitalisation of Eye Gene was ₩74B at the close on Oct 30, 2026.
- Who are the largest shareholders of Eye Gene?
- According to the latest official filings, the largest reported holders are Korea BMI (29.94%, as of May 15, 2026); Yoo Won-il (3.59%, as of Dec 18, 2025); National Pension Service (2.40%, as of Dec 31, 2018).
- When is the next earnings report from Eye Gene?
- Korean companies rarely announce results dates in advance. Based on when Eye Gene filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
- Does the National Pension Service own Eye Gene?
- Yes. The National Pension Service held 2.40% of Eye Gene shares as of Dec 31, 2018.
Company profile
The company is a Korean biotech venture focused on research and development in medicine and pharmaceuticals, with a focus on next-generation gene and cell therapies and vaccines for intractable and genetic diseases. Its main pipelines include an mRNA-based COVID-19 vaccine using a self-amplifying RNA platform developed with consortium partners, and an AAV gene therapy targeting wet age-related macular degeneration and diabetic retinopathy. It also develops a tetravalent meningococcal conjugate vaccine, a recombinant botulinum toxin with Korea BMI, and sells pharmaceuticals through its wholesale business.
Written by AI from the company's latest annual report.
- Korean name
- 아이진
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 최석근
- Founded
- Jun 2000
- Listed
- Nov 2015
- Listed shares
- 43,229,784
- Fiscal year ends
- Month 12
- Website
- www.eyegene.co.kr
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Ajinbio to Build Eye-Snow Avastin-Style Plant? iGeneTec Enters Phase 1/2a Trials Next Year
Predicted impact: Medium
Plans for plant and phase 1/2a trial next year; early-stage, small company with revenue of KRW 4.5 billion.
Recent filings
See all- Amended: Half-year report (Jun 2026)Sep 29, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportAug 3, 2026
- Insider shareholding reportJun 22, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Eye Gene / 아이진 / 185490 / KRX:185490
Source: KRX statistical information